Travere Therapeutics (TVTX) Equity Ratio (2011 - 2026)

Travere Therapeutics has reported Equity Ratio for 16 years, with the latest figure at 0.18 in Q1 2026.

• For the quarter ending Q1 2026, Equity Ratio rose 197.33% year-over-year to 0.18; the trailing twelve-month figure through Mar 2026 stood at 0.18 (up 197.33% YoY), and the FY2025 full-year result was 0.19, up 90.82% from the prior year.
• Equity Ratio for Q1 2026 stood at 0.18, down from 0.19 in the prior quarter.
• The five-year high for Equity Ratio was 0.34 in Q3 2023, with the low at 0.06 in Q3 2024.
• Historically, Equity Ratio has averaged 0.14 across 5 years, with a median of 0.14 in 2022.
• Annual changes were most pronounced in 2024 — Equity Ratio slumped 117.97% — and 2025, when it surged 326.23%.
• Travere Therapeutics' Equity Ratio stood at 0.06 in 2022, then jumped by 299.52% to 0.25 in 2023, then tumbled by 60.94% to 0.1 in 2024, then surged by 90.82% to 0.19 in 2025, then dropped by 6.28% to 0.18 in 2026.
• The last three Equity Ratio figures came in at 0.18 (Q1 2026), 0.19 (Q4 2025), and 0.14 (Q3 2025), per Business Quant data.